Myocardial infarction (MI) is a clinical occurrence brought on by myocardial ischemia in which there is myocardial deterioration or necrosis. Because repairing this damaged myocardium is challenging, researchers have looked into a new stem cell-based heart repair therapy. Mesenchymal stem cells (MSCs) are among the most frequently used cell type for regenerative medicine. MSCs derived from bone marrow (BM-MSCs) are a good choice for cell therapy because they are easy to acquire, have multilineage potential, and have an immunologic advantage. The findings from animal studies support the notion that BM-MSCs have anti-inflammatory, antioxidant, immunomodulatory, anti-apoptotic, and anti-fibrotic effects in cardiovascular disease. These effects significantly reduce cardiomyocyte apoptosis and remodelling effects, which help to improve cardiac function in post-infarction heart failure. In order to determine the potential of stem cell-based therapy for the treatment of MI, a number of clinical trials have been carried out to date. These clinical studies demonstrated that patients with MI who received stem cell therapy had a good safety profile and improved cardiac function. Therefore, the aim of the present study to review the role of MSCs therapy on management of acute myocardial infarction.